McCormack P M, Latham A N, Mee F, Atkins N, O'Brien E T, O'Malley K
Blood Pressure Clinic, Beaumont Hospital, Dublin, Ireland.
J Cardiovasc Pharmacol. 1989;13 Suppl 4:S34-7. doi: 10.1097/00005344-198900134-00009.
The blood-pressure (BP)-lowering efficacy of sustained-release verapamil, using both clinic and ambulatory measurements, was assessed in patients with essential hypertension. In study 1, a between-patient comparison, we compared verapamil (n = 12) with propranolol (n = 10). Dosage of each agent was titrated to achieve optimal clinic BP control and this dose was maintained for the duration of the study. Both agents lowered clinic systolic and diastolic BP. Mean daily ambulatory BP was also reduced with propranolol by 23/8 mm Hg and with verapamil by 13/8 mm Hg. The mean percentage reduction of systolic BP was significantly greater with propranolol (p less than 0.01). In study 2 we assessed the duration of action of sustained-release verapamil (240 mg once daily) in 14 patients. Both clinic and mean ambulatory BP were significantly reduced by 17/12 and 16/8 mm Hg, respectively, and this reduction was maintained throughout the day. We conclude that this formulation of sustained-release verapamil is effective in lowering blood pressure in mild-to-moderate hypertension and that once-daily dosage with 240 mg maintains ambulatory BP reduction throughout the dosing interval.
我们使用临床测量和动态血压测量方法，评估了缓释维拉帕米对原发性高血压患者的降压疗效。在研究1中，我们进行了患者间比较，将维拉帕米组（n = 12）与普萘洛尔组（n = 10）进行对比。滴定每种药物的剂量以实现最佳的临床血压控制，并在研究期间维持该剂量。两种药物均降低了临床收缩压和舒张压。普萘洛尔使平均每日动态血压降低23/8 mmHg，维拉帕米使平均每日动态血压降低13/8 mmHg。普萘洛尔使收缩压的平均降低百分比显著更大（p小于0.01）。在研究2中，我们评估了14例患者中缓释维拉帕米（每日一次，240 mg）的作用持续时间。临床血压和平均动态血压分别显著降低17/12 mmHg和16/8 mmHg，且这种降低在全天都得以维持。我们得出结论，这种缓释维拉帕米制剂对轻至中度高血压患者有效降压，并且每日一次240 mg的剂量在整个给药间隔期内均可维持动态血压降低。
